OverviewSuggest Edit

BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company. It develops immuno-oncology cancer therapies and offers a drug development pipeline which includes a variety of Plinabulin products. The company also provides a preclinical immuno-oncology pipeline that includes BPI-002, BPI-003, and BPI-004 programs.

TypePublic
Founded2010
HQNew York, NY, US
Websitebeyondspringpharma.com
Employee Ratings2.4

Latest Updates

Employees (est.) (Dec 2019)61(+18%)
Share Price (Jan 2021)$12.2 (+3%)
Cybersecurity ratingCMore

Key People/Management at BeyondSpring

Lan Huang

Lan Huang

Co-Founder, Chairman & Chief Executive Officer
Ramon Mohanlal

Ramon Mohanlal

EVP, Research and Development, Chief Medical Officer
Rich Daly

Rich Daly

Chief Operating Officer
Edward Dongheng Liu

Edward Dongheng Liu

Chief Financial Officer, China
Elizabeth Czerepak

Elizabeth Czerepak

Chief Financial Officer
Gordon Schooley

Gordon Schooley

Chief Regulatory Officer
Show more

BeyondSpring Office Locations

BeyondSpring has an office in New York
New York, NY, US (HQ)
28 Liberty St 39th Floor
Show all (1)

BeyondSpring Financials and Metrics

BeyondSpring Revenue

USD

Net income (FY, 2019)

(40.3m)

EBIT (FY, 2019)

(40.3m)

Market capitalization (6-Jan-2021)

478.3m

Closing stock price (6-Jan-2021)

12.2

Cash (31-Dec-2019)

35.9m

EV

446.3m
BeyondSpring's current market capitalization is $478.3 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

1.9m9.1m5.9m9.0m

R&D expense

10.4m88.9m51.6m31.3m

Operating expense total

12.4m98.0m57.5m40.3m

EBIT

(12.4m)(98.0m)57.5m(40.3m)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

General and administrative expense

1.0m2.8m3.3m728.0k1.4m1.5m1.6m2.1m2.5m

R&D expense

46.7m12.2m15.3m14.1m11.0m14.1m6.3m5.2m7.2m

Operating expense total

47.8m15.0m18.6m14.8m12.4m15.7m8.0m7.3m9.7m

EBIT

(47.8m)(15.0m)(18.6m)(14.8m)(12.4m)(15.7m)(7.7m)(7.3m)(9.7m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

11.7m27.5m3.9m35.9m

Prepaid Expenses

360.0k264.0k292.0k410.0k

Current Assets

14.7m32.3m5.9m40.9m

PP&E

80.0k123.0k282.0k209.0k
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(12.5m)(96.4m)(57.5m)(40.3m)

Depreciation and Amortization

18.0k32.0k48.0k77.0k

Accounts Payable

144.0k2.9m6.2m(7.0m)

Cash From Operating Activities

(13.7m)(28.8m)(40.0m)(48.2m)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2019Q1, 2019Q2, 2019Q3, 2019

Net Income

47.7m(62.6m)(80.1m)(14.1m)(26.9m)(42.8m)(7.8m)(15.4m)(25.3m)

Depreciation and Amortization

6.0k13.0k22.0k12.0k20.0k29.0k23.0k41.0k61.0k

Accounts Payable

568.0k1.6m581.0k1.0m(575.0k)(18.0k)(620.0k)(1.1m)(7.6m)

Cash From Operating Activities

(5.3m)(10.4m)(18.6m)(8.9m)(22.0m)(31.6m)(5.1m)(13.1m)(35.5m)
USDFY, 2016

Financial Leverage

1.2 x
Show all financial metrics

BeyondSpring Operating Metrics

FY, 2016Feb, 2018Mar, 2019Mar, 2020

Patents

72 72 76 81

Patents (Plinabulin and Plinabulin Analogs, US)

13 13 16 16

Patents (US)

17 17 20 20

Patent Applications (US)

6 10 14 13
Show all operating metrics

BeyondSpring Acquisitions / Subsidiaries

Company NameDateDeal Size
Beijing Wanchun Pharmaceutical Technology Ltd.
BeyondSpring (HK) Limited
BeyondSpring LTD.
BeyondSpring Pharmaceuticals Inc.
BeyondSpring Pharmaceuticals Australia PTY 
SEED
SEED Technology
Wanchun Biotechnology Limited
Wanchun Biotechnology (Shenzhen) Ltd.
Wanchunbulin

BeyondSpring Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

BeyondSpring Online and Social Media Presence

Embed Graph

BeyondSpring News and Updates

BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present virtually at the 39th Annual J.P. …

BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide th…

BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium

- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone

BeyondSpring to Present at Two Upcoming Scientific Conferences in December

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced a poster presentation about the PROTECTIVE-2 Trial (ClinicalTrials.gov ID: NCT032…

BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that man…

BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates

- Announced SEED Therapeutics Inc.(“SEED”)’s collaboration with Eli Lilly and Company(“Lilly”)
Show more

BeyondSpring Blogs

BeyondSpring’s Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting

Trial Aims to Optimize Chemotherapy by Minimizing Dose Modifications Due to Chemotherapy-Induced Neutropenia or Bone Pain NEW YORK , Dec. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer

BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting

BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting Content Import Mon, 12/09/2019 - 08:01 BeyondSpring’s Abstracts on Clinical Evidence for Bone Marr…

BeyondSpring’s Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019

Premature Patient Drop-Out Rate from Comparator Arm Might Contribute to Negative Trial Outcome, and was Avoided in DUBLIN-3 NEW YORK , Nov. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology

BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources

NEW YORK , Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has appointed Gregg Russo as Senior Vice President, Human Resources,

BeyondSpring Announces Pricing of Ordinary Shares

NEW YORK , Oct. 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its

BeyondSpring Announces Proposed Public Offering of Ordinary Shares

NEW YORK , Oct. 24, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the launch of an
Show more

BeyondSpring Frequently Asked Questions

  • When was BeyondSpring founded?

    BeyondSpring was founded in 2010.

  • Who are BeyondSpring key executives?

    BeyondSpring's key executives are Lan Huang, Ramon Mohanlal and Rich Daly.

  • How many employees does BeyondSpring have?

    BeyondSpring has 61 employees.

  • Who are BeyondSpring competitors?

    Competitors of BeyondSpring include Omeros, Athersys and Otonomy.

  • Where is BeyondSpring headquarters?

    BeyondSpring headquarters is located at 28 Liberty St 39th Floor, New York.

  • Where are BeyondSpring offices?

    BeyondSpring has an office in New York.

  • How many offices does BeyondSpring have?

    BeyondSpring has 1 office.